{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=catridecacog",
    "query": {
      "intervention": "catridecacog"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T08:44:48.938Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00056589",
      "title": "Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2003-03",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056589"
    },
    {
      "nct_id": "NCT02239146",
      "title": "Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Cardiac Surgery Requiring Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 43,
      "start_date": "2005-10",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • San Francisco, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239146"
    },
    {
      "nct_id": "NCT00713648",
      "title": "Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2008-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Orange, California • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713648"
    },
    {
      "nct_id": "NCT01253811",
      "title": "Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Year to 6 Years"
      },
      "enrollment_count": 6,
      "start_date": "2011-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253811"
    },
    {
      "nct_id": "NCT01230021",
      "title": "Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Year to 6 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-11",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230021"
    },
    {
      "nct_id": "NCT00978380",
      "title": "Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2009-09-21",
      "completion_date": "2015-10-20",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 12,
      "location_summary": "Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978380"
    },
    {
      "nct_id": "NCT00914589",
      "title": "Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Cardiac Surgery Requiring Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 479,
      "start_date": "2009-07",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Durham, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914589"
    },
    {
      "nct_id": "NCT01862367",
      "title": "Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Congenital FXIII Deficiency"
      ],
      "interventions": [
        {
          "name": "catridecacog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2013-05-17",
      "completion_date": "2019-06-26",
      "has_results": false,
      "last_update_posted_date": "2019-07-09",
      "last_synced_at": "2026-09-05T08:44:48.938Z",
      "location_count": 7,
      "location_summary": "Orange, California • Tampa, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862367"
    }
  ]
}